Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of TXA127 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients

Trial Profile

A Phase II Trial of TXA127 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Angiotensin-1-7 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Therapeutic Use
  • Sponsors Constant Therapeutics
  • Most Recent Events

    • 28 Feb 2019 According to a LifeArc media release, this trial will be carried out by Constant Therapeutics which, with the additional funding, has been able to add this recessive dystrophic epidermolysis bullosa (RDEB) study to its clinical development plan for TXA127.This trial is expected to begin in 2020.
    • 22 Jan 2019 According to a Constant Therapeutics media release, the company announced that they are changing their name from Constant Pharmaceuticals, LLC, to Constant Therapeutics, LLC.
    • 09 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top